Biogen Inc
NASDAQ: BIIB
$174.46
-$2.48 (-1.4%)
Real Time Data Delayed 15 Min.
BIIB Articles
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
Published:
Denali Therapeutics announced early Thursday that it would be progressing its Parkinson’s treatment into late-stage studies in collaboration with Biogen.
Published:
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Monday's top analyst upgrades and downgrades included Albermarle, Biogen, Dun & Bradstreet, eBay, First Solar, Lemonade, Morgan Stanley, Procter & Gamble, Schlumberger and Verizon Communications.
Published:
24/7 Wall St. looks at some potential winners among Warren Buffett’s holdings. See why they could rally headed toward 2021 and beyond.
Published:
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
Published:
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Monday's top analyst upgrades and downgrades included American Express, Biogen, Discover Financial, DraftKings, Ericsson, Foot Locker, Gap, Kraft Heinz, Nikola, Walmart and Zscaler.
Published: